Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICOMPARE study
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 08 Jun 2021 Results (n=108; data cutoff: 24 Aug 2020) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 12 Mar 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 04 Sep 2013 New trial record